Authors: Kanda, Y Arai, C Chizuka, A Yamamoto, R Hamaki, T Suguro, M Matsuyama, T Takezako, N Miwa, A Tohma, J Shirakawa, K Yatomi, T Nakamura, N Hirai, H Togawa, A

Citation: Y. Kanda et al., Lack of correlation between clinical characteristics and serum soluble Fasligand levels in patients with multiple myeloma, LEUK LYMPH, 40(3-4), 2001, pp. 351-356

Authors: Suzuki, K Endo, R Nakamura, N Yatomi, T Iwai, M Abe, K Takikawa, Y Sato, S

Citation: K. Suzuki et al., Serum levels of soluble Fas ligand in patients with acute and fulminant hepatitis: relationship with soluble Fas, tumor necrosis factor alpha and TNFreceptor-1, HEPATOL RES, 17(1), 2000, pp. 19-30

Authors: Kanda, Y Chiba, S Tanaka, Y Kami, M Saito, T Izutsu, K Asai, T Yuji, K Ogawa, S Honda, H Mitani, K Usuki, K Urabe, A Shirakawa, K Yatomi, T Nakamura, N Yazaki, Y Hirai, H

Citation: Y. Kanda et al., Increased serum soluble Fas ligand associated with recurrent B-cell non-Hodgkin's lymphoma after autologous peripheral blood stem cell transplantation, LEUK LYMPH, 34(5-6), 1999, pp. 625-628

Authors: Miwa, K Hashimoto, H Yatomi, T Nakamura, N Nagata, S Suda, T

Citation: K. Miwa et al., Therapeutic effect of an anti-Fas ligand mAb on lethal graft-versus-host disease, INT IMMUNOL, 11(6), 1999, pp. 925-931

Authors: Kakinuma, C Takagaki, K Yatomi, T Nakamura, N Nagata, S Uemura, A Shibutani, Y

Citation: C. Kakinuma et al., Acute toxicity of an anti-Fas antibody in mice, TOX PATHOL, 27(4), 1999, pp. 412-420

Authors: Kuwano, K Hagimoto, N Kawasaki, M Yatomi, T Nakamura, N Nagata, S Suda, T Kunitake, R Maeyama, T Miyazaki, H Hara, N

Citation: K. Kuwano et al., Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis, J CLIN INV, 104(1), 1999, pp. 13-19